Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Atlas Venture's Bruce Booth: 'IFM's programs complement the existing Novartis pipeline of anti-inflammatory medicines, and build off of the strong clinical…
Bradner (Novartis): NLRP3 antagonists allow Novartis to 'fine-tune the immune system'; IFM CEO Glick called the deal a 'significant milestone' validating…
Phase 2 trial of DFV890 (formerly IFM-2427, the lead oral systemic NLRP3 antagonist from IFM Tre) in coronary heart disease with elevated hsCRP. Confirms…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Novartis acquired IFM Therapeutics' subsidiary IFM Tre for $310M upfront plus up to $1.265B in contingent milestones. Adds three preclinical NLRP3 antagonist programs (oral systemic, gut-targeted, CNS-penetrant) for inflammatory diseases.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / IFM Tre, Inc. (this deal) | 2019 | $1.6B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2019 deals · Novartis AG deals · Cardiovascular deals